U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524348) titled 'A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors' on March 26.
Brief Summary: This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Study Start Date: March 23
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: E303
All participants will receive an intravenous (IV) infusion of E303
Recruitment Status: RECRUITING
Sponsor: Samsung Bioepis Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....